Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Solid tumors save search
Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Published: 2022-03-03 (Crawled : 21:00) - cytomx.com
CTMX | $1.735 -1.42% -1.44% 200K
|
Health Technology
|
| O: -1.57%
H: 2.66%
C: -1.33%
cd166 solid tumors cd16 drug trial label antibody
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
Published: 2022-01-31 (Crawled : 14:00) - biospace.com/
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 0.0%
H: 13.69%
C: 11.2%
solid tumors phase 1b trial therapeutics phase 1 positive phase 2b
ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications
Published: 2022-01-25 (Crawled : 14:00) - globenewswire.com
ORIC | $9.5 -2.66% -2.74% 590K
|
Health Technology
|
| O: -2.06%
H: 3.2%
C: -1.1%
oric-114 als clearance solid tumors application trial her2- her2
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
HCWB | $1.59 0.0% 2.6K
|
|
| O: 5.45%
H: 0.47%
C: 0.0%
hcw9218 fda clearance solid tumors trial fda clearance phase 1 cancer
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
Published: 2022-01-20 (Crawled : 13:00) - biospace.com/
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 1.57%
H: 19.97%
C: 12.85%
xtx202 treatment solid tumors trial therapeutics phase 1
HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Published: 2022-01-20 (Crawled : 01:00) - globenewswire.com
HCM | $16.36 -0.55% -0.43% 190K
|
Health Technology
|
| O: -3.16%
H: 3.83%
C: -0.2%
hmpl-653 solid tumors trial china
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -8.6%
H: 5.62%
C: 2.83%
phase 2 solid tumors trial china
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
Published: 2022-01-13 (Crawled : 14:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -3.17%
H: 2.64%
C: -6.86%
rtx-224 treatment solid tumors trial therapeutics phase 1
GenomOncology Pathology Workbench to Support OmniSeq INSIGHT℠, a Genomic and Immune Profiling Test That Identifies Potential Treatment and Clinical Trial Options for Solid Tumors
Published: 2022-01-12 (Crawled : 20:00) - biospace.com/
LH M | $199.45 -0.26% 0.27% 770K
|
Health Services
|
| O: -1.49%
H: 0.0%
C: -1.67%
treatment solid tumors genomic trial potential work test
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
Published: 2022-01-06 (Crawled : 14:30) - biospace.com/
BOLT | $1.15 3.6% 3.48% 89K
|
|
| O: -4.05%
H: 2.98%
C: -7.2%
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -1.17%
H: 0.11%
C: -0.39%
bdc-1001 opdivo treatment solid tumors ongoing trial therapeutics 100 phase 1 iot her2- her2 nivolumab
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
MGNX | $16.07 -0.19% -0.12% 660K
|
Health Technology
|
| O: -0.75%
H: 1.28%
C: -2.84%
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -0.49%
H: 2.25%
C: -0.79%
phase 2 solid tumors trial approval china
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
RPTX 4 | $3.02 -5.92% -6.12% 140K
|
Health Technology
|
| O: 2.22%
H: 3.86%
C: 2.64%
rp-6306 treatment solid tumors trial therapeutics phase 1 gemcitabine
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Published: 2021-12-15 (Crawled : 15:30) - biospace.com/
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -11.41%
H: 8.08%
C: 7.32%
solid tumors trial approval phase 1 china antibody phase 2
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.18%
H: 2.11%
C: 1.66%
NKTR | $1.3 -3.7% -3.85% 3.6M
|
Health Technology
|
| O: 0.16%
H: 2.52%
C: 2.05%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.59%
H: 5.8%
C: 5.68%
xl092 solid tumors phase 1b trial phase 1 phase 2b
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
Published: 2021-12-03 (Crawled : 13:30) - biospace.com/
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -5.2%
H: 0.0%
C: 0.0%
phase 2 solid tumors trial
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
Published: 2021-11-19 (Crawled : 13:30) - globenewswire.com
RAIN | $1.21 0.0% 3.7M
|
Manufacturing
|
| O: 0.0%
H: 0.79%
C: -5.22%
phase 2 solid tumors trial
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
SRRK A | $13.96 1.9% 1.86% 860K
|
Health Technology
|
| O: -0.35%
H: 3.45%
C: 2.09%
treatment solid tumors phase 1 therapy trial
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Published: 2021-11-09 (Crawled : 14:00) - immatics.com
IMTX | $10.26 0.29% 0.29% 440K
|
Health Technology
|
| O: 0.08%
H: 2.07%
C: -13.92%
ongoing phase 1 trial ima203 solid tumors response phase 1b
Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 InhibitorPhase 1 Clinical Trial in Patients with Selected Solid Tumors Anticipated to Begin by Year-End
Published: 2021-11-08 (Crawled : 15:00) - biospace.com/
PRLD | $3.44 -17.7% -21.51% 110K
|
Health Technology
|
| O: 1.69%
H: 1.49%
C: -0.4%
solid tumors phase 1 trial clearance
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
Published: 2021-11-04 (Crawled : 11:00) - biospace.com/
BCYC | $24.51 12.33% 10.98% 700K
|
Health Technology
|
| O: 1.79%
H: 0.86%
C: -0.05%
solid tumors trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.